Lexaria’s DehydraTECH-CBD Lowers Blood Pressure

Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability
Lexaria Bioscience

Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is extremely pleased to issue partial results from human clinical study HYPER-H21-1 evaluating DehydraTECHTM-processed cannabidiol (“CBD”) for potential application against hypertension. Partial results related to blood pressure (“BP”) are being released today, while additional BP subset analyses and all other data analyses including pharmacokinetic (“PK”) evaluations and detailed blood chemistry work is in progress and will be released when complete. read more

DehydraTECH(TM) – Enabled Consumer Products Now Available in Over 7,000 Stores

Lexaria’s technology empowers brands nationwide in stores including Albertsons, Hudson News, and many more
Lexaria Bioscience

Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce that its DehydraTECHTM technology has been embraced by consumer brands now available for sale in over 7,000 stores across the US. read more

Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2

Additionally, second patent award received in Japan
Lexaria Bioscience

Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce that dosing has been completed in its second human clinical study of 2021. read more

Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy

All objectives evaluating DehydraTECH™ drug delivery platform successfully achieved
Lexaria Bioscience
  read more

Lexaria’s DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3

Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects
Lexaria Bioscience
DrugCmax* % Improvement
(ng/mL)
Control
(ng/mL)
AUClast** % Improvement
(hr∙ng/mL)
Control
(hr∙ng/mL)
Colchicine31.97
91%
(p=0.0005)
16.73104.43
167%
(p=0.0028)
38.97

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. read more

Lexaria Completes Successful Antiviral Drug Molecular Characterization Study with Canada’s National Research Council

VIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral Drugs
Lexaria Bioscience

Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce results from its antiviral drug molecular characterization study VIRAL-MC21-1 recently completed by Canada’s premier federally funded research organization, the National Research Council (“NRC”). read more

Lexaria Receives Patent Protection in Japan

New patent granted in Japan adds to existing patents in the EU, the U.S., India and Australia
Lexaria Bioscience

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces an additional expansion of its intellectual property portfolio with its first-ever patent granted in Japan. read more

Lexaria: A drug delivery system

LEXX, Lexaria Bioscience

It is one thing to have a drug which shows activity against an infection, virus or disease, it is another to deliver that drug effectively. Lexaria (NASDAQ:LEXX) is in the drug delivery business. Whether it is an anti-viral like COVID-19 focused Remdesivir and Ebastine or Cannabinoids including for Hypertension and Central Nervous System disorders, Lexaria’s DehydraTECH™ technology has the potential to enhance the performance of those drugs. read more

Magazine Plus by WEN Themes